Cantargia AB (publ) (CANTA) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon, everyone, and welcome to Contarga's year-end presentation for the fourth quarter and full year of 2025. I'm Hilde Steininger, CEO, and with me, I have our CFO, Patrik Renblad. We'll walk you through the operational highlights, pipeline updates, key clinical developments and financial results, and then open the line for Q&A. Next slide. Before we Please note that today's discussion includes forward-looking statements. These statements involve risk and uncertainties and actual outcomes may differ materially. We do not undertake any obligation to update them except required by law. Please review the Safe Harbor slide for details. Once again, I'm Hilde Steininger joined by Patrik. I'll start with the strategic and clinical overview. Patrik will then cover the financials and cash positions. We will conclude with closing remarks and time for questions. Next slide. In Q4, we appointed Dr. Wolfram Dempke as our chief medical officer, adding deep clinical and regulatory expertise to our leadership team. During the quarter, we also reported overall survival data from our phase 1B2 triforce triple negative breast cancer trial, which showed no difference in median overall survival between non-Nolimod plus standard of care compared to standard of care alone. Importantly, after the period, the first patient was dosed in an investigator-initiated trial, at Mount Sinai, New York, evaluating Nadenolumab in combination with a checkpoint inhibitor in colorectal cancer. The initiation of this externally sponsored study by a leading US academic cancer center underlies the growing recognition among prominent clinical institutions of Nadenolumab's potential and scientific relevance across tumor types. Such institutional engagement reinforced confidence in the clinical ratio...